Medifast (MED) Net Income towards Common Stockholders (2010 - 2026)

Medifast's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$2.1 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 176.61% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.0 million (down 187.98% YoY) and the FY2025 annual result came in at -$18.6 million, down 991.39% from the prior year.
• Net Income towards Common Stockholders was -$2.1 million for Q1 2026 at Medifast, up from -$18.1 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $41.8 million in Q1 2022 and bottomed at -$18.1 million in Q4 2025.
• A 5-year average of $13.2 million and a median of $6.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 130.43% in 2025, while the deepest fall reached 2357.43% in 2025.
• Medifast's Net Income towards Common Stockholders stood at $26.5 million in 2022, then sank by 77.24% to $6.0 million in 2023, then sank by 86.73% to $801000.0 in 2024, then tumbled by 2357.43% to -$18.1 million in 2025, then soared by 88.16% to -$2.1 million in 2026.
• Business Quant data shows MED's Net Income towards Common Stockholders at -$2.1 million in Q1 2026, -$18.1 million in Q4 2025, and -$2.3 million in Q3 2025.